Development of resistance to various therapeutic agents is contributing to increasing demand for immuno-specific drugs and vaccines. In this regard, scientists have noted that the production of monoclonal antibodies for canine atopic dermatitis treatment could prove largely helpful, and could be more stable as compared to biological drugs, which will create opportunity for the growth of the canine atopic dermatitis treatment market.
FMI – a well-established name in the market research domain – forecasts that, the canine atopic dermatitis treatment market will experience a major upturn post 2026, reaching US$ 2.4 Bn by 2029.
As per a detailed study by Future Market Insights, the demand in the global canine atopic dermatitis treatment market is projected to total US$ 1.05 Bn by 2022, surging at an impressive CAGR of 12.3% over the forecast period 2022-2029.
FMI estimates that North America will emerge as the most remunerative canine atopic dermatitis treatment market, creating an incremental opportunity of US$ 1 Bn through 2029. Based on the route of administration, the oral segment is anticipated to dominate the market, accounting for nearly 48.2% of the revenue share by 2022.
Request a report sample to gain comprehensive insights at
https://www.futuremarketinsights.com/reports/sample/rep-gb-4412
| Attribute | Details |
| Canine Atopic Dermatitis Treatment Market Estimated Size in 2022 | US$ 1.05 Bn |
| Canine Atopic Dermatitis Treatment Market Projected Size in 2029 | US$ 2.37 Bn |
| Canine Atopic Dermatitis Treatment Market Historical CAGR (2014-2021) | 13.8% |
| Canine Atopic Dermatitis Treatment Market Value-based CAGR (2022-2029) | 12.3% |
Key Takeaways of Canine Atopic Dermatitis Treatment Market Study
- Immunosuppressants are anticipated to be highly preferred treatment for canine atopic dermatitis, and contribute more than 45% revenue share in the canine atopic dermatitis treatment market.
- Due to growing resistance to various therapeutic chemical agents, the demand for high specificity biologics such as monoclonal antibodies is expected to increase during the forecast period.
- The injectable segment is anticipated to dominate the market by route of administration for administrating monoclonal antibodies.
- In terms of distribution channel, retail pharmacies are expected to gain more than 50% of market share during the forecast period.
- North America is the dominating region, while East Asia is expected to offer lucrative opportunities, owing to rapid increase in healthcare programs and industrialization.
For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-4412
Leading Manufacturers Following Acquisition Strategy to Increase Regional Presence
Leading manufacturers in the canine atopic dermatitis treatment market are focusing on regional acquisitions to enhance their product portfolios and expand their regional presence. For instance, in 2021, Zoetis completed the acquisition of Nexvet Biopharma. This collaboration strengthened the development platform of mAb therapies and added new alternatives to treat diseases in companion animals.
In 2021, Elanco Animal Health (Eli Lily and Company) reported an acquisition of Boehringer Ingelheim Vetmedica, Inc., which includes an array of rabies vaccines, feline and canine products, and several pipeline assets.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-4412
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain
Canine Weight Loss Drugs Market – With the millions of Americans being overweight, a large number of canine companions comprising about 20% to 30% of dogs are overweight in the United States. Two main reasons for dogs being overweight are too little exercise and over eating.
Canine Atopic Dermatitis Treatment Market – The global Canine Atopic Dermatitis Treatment Market is estimated to exceed US$ 2.37 Bn by the end of 2029. Growing emphasis on the development of novel therapeutics such as monoclonal antibodies for the treatment of atopic dermatitis in dogs and cats is expected to favor the growth in the market.
Canine Flu Therapeutics Market – Canine flu (also known as dog flu) is a contagious respiratory disease in dogs mainly caused by Type A influenza/canine influenza virus. They are two various kinds of influenza viruses namely H3N8 virus and H3N2.
Feline Atopic Dermatitis Treatment Market – Feline atopic dermatitis is the inflammation of the skin seen in the cats. Feline atopic dermatitis is often triggered by causative allergens which are either inhaled or through skin contact leading to inflammation of the skin.
Microparticle Injectables Market – According to the latest research by FMI, Microparticle Injectables are set to witness a steady-paced growth of CAGR 5.8% during the year 2021-2031. Microparticle Injectables are broadly used constituents of multiparticulate drug delivery systems, offering both technological and therapeutic advantages.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/